Skip to Main Content

Paper Details

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Blood
58
2022
CAR, CAR T, CAR-T, CD19, ICANS, PCNSL, T, T-cell, Tisagenlecleucel, chimerical antigen receptor, cytokine release syndrome, immune cell-associated neurotoxicity syndrome, macrophage, macrophage gene signatures, patient, patients, primary CNS lymphoma, primary central nervous system (CNS) lymphoma, systemic large B-cell lymphoma
Author NameAffiliation
Nora HorickMassachusetts General Hospital
Areej El-JawahriMassachusetts General Hospital and Harvard Medical School
Tracy T BatchelorBrigham's and Women Hospital & Dana Farber Harvard Cancer Institute
Tracy T BatchelorBrigham's and Women Hospital & Dana Farber Harvard Cancer Institute
  • 1 - 4

Datasets

Release 1.2